These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Project Optimus seeks to transform how doses are selected and optimised in oncology drug development. As this initiative ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its target price decreased by analysts at The Goldman Sachs Group from $22.00 to ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12 ...

Detailed price information for Medpace Holdings Inc (MEDP-Q) from The Globe and Mail including charting and trades.

The company's backlog, which consists of anticipated future revenue from business awards, stood at $7.7 billion as of ...

Q4 2024 Earnings Call Transcript March 3, 2025 Fortrea Holdings Inc. misses on earnings expectations. Reported EPS is $0.18 ...

BofA lowered the firm’s price target on Fortrea (FTRE) to $10 from $17 and keeps an Underperform rating on the shares after a Q4 miss and FY25 ...

We reduced our fair value estimate to $15.50 per share from $27.20 to account for greater headwinds as a newly stand-alone company since its spinoff from Labcorp in 2023, which will weigh on revenue ...

Shares of Fortrea Holdings sank to a new low after the company said it expects revenue to drop this year. The stock fell 31% to a new all-time low of $9.55 in the first half of the trading day. The ...

Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 18.5% in the pre-market session after the company ...

The contract-research organization expects $2.45 billion to $2.55 billion in revenue for 2025, down from $2.7 billion last year. Analysts polled by FactSet had been forecasting a small gain to $2.73 ...